S-甲基二氢西普拉西酮-d8 | 194280-91-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: S-甲基二氢西普拉西酮-d8
• 英文名称: S-Methyldihydroziprasidone
• 英文别名: 6-chloro-5-(2-{4-[imino-(2-methylsulfanylphenyl)-methyl]-piperazin-1-yl}-ethyl)-1,3-dihydro-indol-2-one；6-chloro-5-[2-[4-(2-methylsulfanylbenzenecarboximidoyl)piperazin-1-yl]ethyl]-1,3-dihydroindol-2-one
• CAS: 194280-91-6
• 化学式: C₂₂H₂₅ClN₄OS
• 分子量: 428.986
• InChiKey: NHUDBVVEHOSVCD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  84.7
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Methods and compositions for the treatment of neuroleptic and related disorders using ziprasidone metabolites
  申请人：Barberich J. Timothy

  公开号：US20060019970A1

  公开（公告）日：2006-01-26

  The invention relates to novel methods using, and pharmaceutical compositions comprising, ziprasidone metabolites. The methods and compositions of the invention are suitable for the treatment of neuroleptic and related disorders. The invention further encompasses methods of preparing ziprasidone sulfoxide and ziprasidone sulfone.

  该发明涉及使用新方法和包含氮平代谢物的药物组合物。该发明的方法和组合物适用于治疗抗精神病药和相关疾病。该发明还涵盖了制备氮平亚砜和氮平砜的方法。
• S-methyl-dihydro-ziprasidone for treatment of psychiatric disorders
  申请人：Pfizer Products Inc.

  公开号：EP1468686A2

  公开（公告）日：2004-10-20

  This invention relates to pharmaceutical compositions containing S-methyl-dihydroziprasidone and to the use of such compound and its pharmaceutically acceptable salts for the treatment of psychiatric disorders. More specifically, it relates to the use of such compound and its pharmaceutically acceptable salts for the treatment of a disorder or condition selected from: schizophrenia, anxiety disorders such as generalized anxiety disorder, panic disorder, posttraumatic stress disorder and phobias (e.g., social phobia, agoraphobia etc.); psychotic episodes of anxiety: anxiety, agitation, excessive aggression, tension, or social or emotional withdrawal associated with psychosis; psychotic mood disorders such as severe major depressive disorder; mood disorders associated with psychotic disorders such as acute mania and depression associated with bipolar disorder, and mood disorders associated with schizophrenia; behavioral disturbances associated with mental retardation, autistic disorder, and conduct disorder; dementias such as dementias associated with Alzheimer's disease; drug-induced and neurodegeneration based dyskinesias; obsessive compulsive disorder; and Tourette's syndrome.

  本发明涉及含有S-甲基-二氢齐拉西酮的药物组合物，以及该化合物及其药学上可接受的盐用于治疗精神疾病的用途。更具体地说，本发明涉及此类化合物及其药学上可接受的盐类用于治疗选自以下疾病或病症的用途：精神分裂症、焦虑症，如广泛性焦虑症、惊恐障碍、创伤后应激障碍和恐惧症（如：社交恐惧症、惧郁症）、社交恐惧症、恐旷症等。焦虑性精神病发作：与精神病相关的焦虑、激动、过度攻击、紧张或社交或情感退缩；精神病性情绪障碍，如严重的重度抑郁障碍；与精神病相关的情绪障碍，如与双相情感障碍相关的急性躁狂和抑郁，以及与精神分裂症相关的情绪障碍；与智力迟钝、自闭症和行为障碍相关的行为紊乱；痴呆症，如与阿尔茨海默氏症相关的痴呆症；药物诱发和神经变性引起的运动障碍；强迫症；抽动秽语综合征。
• S-methyl-dihydro-ziprasidone for the treatment of schizophrenia
  申请人：Pfizer Products Inc.

  公开号：EP1698338A2

  公开（公告）日：2006-09-06

  This invention relates to the use of 6-chloro-5-(2-4-[imino-(2-methylsulfanylphenyl)-methyl]-piperazin-1-yl}-ethyl)-1,3-dihydro-indol-2-one,or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating schizophrenia in a mammal.

  本发明涉及 6-氯-5-(2-4-[亚氨基-(2-甲硫基苯基)-甲基]-哌嗪-1-基}-乙基)-1,3-二氢-吲哚-2-酮或其药学上可接受的盐在制造治疗哺乳动物精神分裂症的药物中的用途。
• METHODS AND COMPOSITIONS FOR THE TREATMENT OF PSYCHOTIC AND RELATED DISORDERS USING ZIPRASIDONE METABOLITES
  申请人：Sepracor Inc.

  公开号：EP1165083A2

  公开（公告）日：2002-01-02
• S-methyl-dihydro-ziprasidone for the treatment of ocular disorders.
  申请人：Pfizer Products Inc.

  公开号：EP1286672B1

  公开（公告）日：2006-10-25